312 results
Name Type Target Compound Name Phase
Michigan State University

High Accuracy Modeling of SARS-CoV-2 Membrane Proteins via Machine Learning and Physics-Based Refinement

Research (Modeling) N/A N/A Research
University of California, Riverside

Harnessing Large-Scale Quantum-Based DFTB Calculations for a More Accurate Assessment of COVID-19 Inhibitors and Their Binding Dynamics

Research (Modeling) N/A N/A Research
University of California, Riverside

Computer-aided drug discovery for SARS-CoV-2

Research (AI) N/A N/A Pre-Clinical
Emory University

Characterization and structures of the SARS-CoV-2 polymerase and its complex with RNA or potential inhibitors

Research (Modeling) N/A N/A Research
Kaiser Family Foundation (KFF)

Communities of Color at Higher Risk for Health and Economic Challenges due to COVID-19

Research (Epidemiology) N/A N/A Pre-Clinical
Imperial College COVID-19 Response Team

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand

Research (Epidemiology) N/A N/A Research
Collaboration: The University of Hong Kong; Harvard T.H. Chan School of Public Health

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Research (Epidemiology) N/A N/A Pre-Clinical
Collaboration: Michigan State University; University of Illinois at Chicago;

Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine

Research (Modeling) N/A N/A Pre-Clinical

This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state.

Research (Modeling) N/A N/A Research
Collaboration: Women’s Hospital Heart and Vascular Center; Harvard Medical School; Baylor College of Medicine; Christ Hospital; University of Utah; HCA Research Institute

Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with COVID-19

New Therapies (Antibody-based) N/A N/A Pre-Clinical

Grifols collecting plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.

New Therapies (Small Molecule) N/A Alpha-1 antitrypsin Pre-Clinical

Kerecis Begins Omega3 Viruxide COVID-19 Trial at the National Hospital of Iceland

New Therapies (Lipid) N/A Omega3 Viruxide In Clinic

The FDA recommended that Revive Therapeutics proceed directly into a Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine.

N/A Bucillamine Phase III
Shenyang Tonglian

The Clinical Study of Carrimycin on Treatment Patients With COVID-19

New Therapies (Small Molecule) N/A Carrimycin Phase IV
CUNY Institute for Implementation Science in Population Health

The study team moved quickly to enroll a prospective cohort of >7,000 individuals using internet-based strategies. The cohort represents a geographically and socio-demographically diverse sample of the adult U.S. population: 23 percent of participants were 60+ years at enrollment, 24 percent are Black or Hispanic, and 52 percent are men. At least 24 percent of participants are frontline workers, either in healthcare or other essential employees such as police, first responders, people in food services or transportation. All fifty U.S. states are represented, as well as the District of Columbia, Puerto Rico, and Guam.

Research (Epidemiology) N/A N/A Research
Collaboration: Cytovia; Macromoltek

Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)

New Therapies (Antibody-based) NCR1, NKP46, CD335 NK activating Abs + neutralizing antibodies Pre-Clinical
Vanda Pharmaceuticals

Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

New Therapies (Protein-based) NK1R; TACR1 Tradipitant Phase III
Algernon Pharmaceuticals

Toxicology studies initiated for anti-inflammatory drug ifenprodil

Research (Drug Repurposing) NMDA receptor NR2B (GRIN2B; NR2B; GluN2B) Ifenprodil (NP-120) IND
Fasa University of Medical Sciences

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

New Therapies (Small Molecule) Nicotinic acetylcholine receptor (nAchR) Levamisole Phase II / III
Vanda Pharmaceuticals

Amantadine disrupts lysosomal gene expression; potential therapy for COVID19

New Therapies (Small Molecule) Not determined Amantadine Pre-Clinical
Cleveland Clinic

Network-based drug re-purposing for novel coronavirus 2019-nCoV/SARS-CoV-2

New Therapies (Small Molecule) Not determined Dactinomycin Pre-Clinical
Cleveland Clinic

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

New Therapies (Small Molecule) Not determined Mercaptopurine Pre-Clinical

Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19

New Therapies (Small Molecule) Not determined VivaGel Pre-Clinical
WanBangDe Pharmaceutical

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

New Therapies (Small Molecule) Not determined Bromhexine hydrochloride In Clinic

FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19

New Therapies (Small Molecule) Not determined FW-1022 (oral niclosamide) Phase II